Latest Market Entry News

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Actinogen Medical advances its XanaMIA phase 2b/3 Alzheimer’s trial with faster patient enrolment and expands clinical sites, while achieving a pivotal FDA meeting outcome for its depression program. The company maintains a strong cash position, supporting ongoing development and commercialization efforts.

PainChek Limited reports strong progress toward FDA De Novo clearance for US market entry, launches its Infant App in Australia, and achieves robust global licence growth with a 30% year-on-year revenue increase.

Iondrive Limited confirms strong financial metrics for its proprietary DES battery recycling technology, progressing pilot plant development and divesting exploration assets to sharpen focus on commercialisation.

LTR Pharma reports strong Q1 2025 progress with FDA pre-IND meeting success, scientific acclaim for SPONTAN’s rapid absorption, and strategic launch of ROXUS to fast-track US market entry.

Nuchev Limited reported a remarkable 215% increase in quarterly revenue, driven by the strategic launch of Oli6® in Vietnam and the acquisition of bWellness, signaling robust expansion across key Asia-Pacific markets.

Decidr AI Industries signals a strategic pivot to AI with a successful $11 million capital raise, new multi-year contracts, and expanded global partnerships, driving early commercial traction and robust e-commerce growth.

Sprintex Limited has advanced its commercial and technological milestones with major European and Indian orders, breakthrough energy efficiency validation, and a successful A$3.25 million equity raise, positioning the company for accelerated growth.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.

Alcidion Group Limited reported a robust Q3 FY25 with $13.1 million in cash receipts and a landmark 10-year $37.5 million contract with North Cumbria NHS Trust, prompting an upgrade to its full-year EBITDA guidance.

Memphasys has initiated clinical utility testing of its Felix™ System in Brazil through a partnership with Laboratorio Androscience, aiming to establish a foothold in the rapidly growing Latin American IVF sector.

Recce Pharmaceuticals reports strong Phase II results for its RECCE® 327 topical gel, achieving a 93% efficacy rate in treating serious skin infections and setting the stage for accelerated Phase 3 trials.